Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reldesemtiv phase 3 trial in amyotrophic lateral sclerosis
NL-OMON52262Phase 3Active, not recruiting
- Sponsor
- Cytokinetics
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Reldesemtiv with Placebo (2 arms). Primary endpoint: Change from baseline to Week 24 in ALSFRS-R total score. Started Jan 2022; status: active, not recruiting.
02
Drugs
reldesemtiv
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON52262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52262.